美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Versartis Inc

7.14

0.0000

成交量：- -

成交额：- -

市值：4,312.64万

市盈率：-6.81

高：7.14

开：7.14

低：7.14

收：7.14

52周最高：7.14

52周最低：1.14

股本：604.01万

流通股本：604.01万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.0488

每股收益(LYR):-2.4123

净资产收益率：--

总资产收益率：--

市净率：0.63

市盈率(LYR):-2.96

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Versartis Inc

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.versartis.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Versartis, Inc.是一家发展阶段的公司，于2008年12月10日在特拉华州成立。公司是一家以内分泌为重点的生物制药公司，最初为生长激素缺乏（或生长激素缺乏症），一种孤儿病开发其新颖的长效重组人生长激素——VRS-317。目前的重组人生长激素（rhGH）的一个关键限制产品是他们多年强加每天注射的负担，往往造成依从性差，这反过来又可以导致生长激素缺乏症患者最理想的治疗效果。尽管有此限制，全球年销售额从目前销售的重组人生长激素产品在过去5年每年约6％的增长到2012年超过30亿。VRS -317的目的是通过要求显著较少的注射以减少日常处理的负担，有可能改善合规性和治疗效果。公司的第一个VRS- 317的目标适应是小儿生长激素缺乏症，它代表一个约15亿的现有市场机会。Versartis目前正在进行小儿生长激素缺乏症的临床试验中，公司正在评估每周、每半月和每月给药方案的2a阶段。Versartis为成人生长激素缺乏症、特发性矮小（或ISS）发展VRS -317，这是一种原因不明的身材矮小特纳综合征，这是女性的X染色体赤字或删除。成人生长激素缺乏症，ISS和特纳氏综合症在一起占全球重组人生长激素市场的约30％。Versartis对VRS- 317有全球性的权利。如果VRS -317被批准后并给予了高度集中的处方基地，Versartis打算在美国和加拿大以及潜在的其他地区使自己的专业销售队伍商业化。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/VSAR/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VSAR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","market":"US","secType":"STK","nameCN":"Versartis Inc","latestPrice":7.14,"timestamp":1539633599999,"preClose":7.14,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":6040109,"shares":6040109,"eps":-1.048764,"marketStatus":"盘前交易","change":0,"latestTime":"03-19 04:19:31 EDT","open":7.14,"high":7.14,"low":7.14,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.048764,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773927000000},"marketStatusCode":1,"symbolChange":{"newSymbol":"ARAV","executeDate":"2018-10-16"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.14,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","floatShares":6040109,"roa":"--","roe":"--","lyrEps":-2.412257,"shares":6040109,"dividePrice":0,"high":7.14,"amplitude":0,"preClose":7.14,"low":7.14,"week52Low":1.14,"pbRate":"0.63","week52High":7.14,"institutionHeld":0,"latestPrice":7.14,"eps":-1.048764,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.048764,"open":7.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VSAR\",params:#limit:5,,,undefined,":[{"date":"2018-10-16","symbol":"VSAR","newSymbol":"ARAV","type":"symbolChange","dateTimestamp":1539662400000},{"market":"US","date":"2018-08-07","symbol":"VSAR","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.27},{"market":"US","date":"2018-05-08","symbol":"VSAR","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"","actualEps":-0.25},{"market":"US","date":"2018-03-01","symbol":"VSAR","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"","actualEps":0.87},{"market":"US","date":"2017-10-26","symbol":"VSAR","fiscalQuarterEnding":"2017/09","expectedEps":-0.68,"name":null,"time":"","type":"earning","dateTimestamp":1508990400000,"reportTimeType":"","actualEps":-1.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VSAR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.versartis.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Versartis, Inc.是一家发展阶段的公司，于2008年12月10日在特拉华州成立。公司是一家以内分泌为重点的生物制药公司，最初为生长激素缺乏（或生长激素缺乏症），一种孤儿病开发其新颖的长效重组人生长激素——VRS-317。目前的重组人生长激素（rhGH）的一个关键限制产品是他们多年强加每天注射的负担，往往造成依从性差，这反过来又可以导致生长激素缺乏症患者最理想的治疗效果。尽管有此限制，全球年销售额从目前销售的重组人生长激素产品在过去5年每年约6％的增长到2012年超过30亿。VRS -317的目的是通过要求显著较少的注射以减少日常处理的负担，有可能改善合规性和治疗效果。公司的第一个VRS- 317的目标适应是小儿生长激素缺乏症，它代表一个约15亿的现有市场机会。Versartis目前正在进行小儿生长激素缺乏症的临床试验中，公司正在评估每周、每半月和每月给药方案的2a阶段。Versartis为成人生长激素缺乏症、特发性矮小（或ISS）发展VRS -317，这是一种原因不明的身材矮小特纳综合征，这是女性的X染色体赤字或删除。成人生长激素缺乏症，ISS和特纳氏综合症在一起占全球重组人生长激素市场的约30％。Versartis对VRS- 317有全球性的权利。如果VRS -317被批准后并给予了高度集中的处方基地，Versartis打算在美国和加拿大以及潜在的其他地区使自己的专业销售队伍商业化。","exchange":"NASDAQ","name":"Versartis Inc","nameEN":"Versartis"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":null}}